HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress.

Abstract
Neuropilin-1 (NRP-1) is a transmembrane glycoprotein. As a VEGF co-receptor, NRP1 significantly enhances VEGFR2 signaling and promotes vascular permeability and migration. The purpose of this study was to evaluate the effects of an NRP-1 inhibitor, ATWLPPR peptide, on the early stages of diabetic retinopathy. Eight-week-old male C57BL/6 mice were divided into three groups: a Normal group, a Diabetes (DB) ATWLPPR treatment group and a DB saline group. Electroretinography (ERG), fundus fluorescence angiography (FFA) and leukostasis were examined to evaluate the retinal injury induced by diabetes at the end of the fifth week after STZ injection. Occludin expression and extravasation of albumin were measured to determine the extent of vascular injury. The oxidative stress level and the levels of inflammation-associated proteins were also assayed. The results indicated that treatment with ATWLPPR prevents the abnormal condition of ERG (amplitudes of b-wave decreased and implicit time increased) and vascular injury (occludin degradation and increase in extravasated albumin). These effects were associated with a reduction in the oxidase stress level and the expression of VEGF, GFAP, and ICAM-1. We conclude that ATWLPPR, an NRP-1 inhibitor, may reduce the early retinal damage induced by diabetes by preserving vascular integrity and decreasing the oxidative stress level. Blockade of NRP-1 may be a new therapeutic strategy for the early stages of DR.
AuthorsJun Wang, Shuaiwei Wang, Mengling Li, Dongdong Wu, Fang Liu, Ruisheng Yang, Shaoping Ji, Ailing Ji, Yanzhang Li
JournalPloS one (PLoS One) Vol. 10 Issue 11 Pg. e0142571 ( 2015) ISSN: 1932-6203 [Electronic] United States
PMID26554379 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Ala-Thr-Trp-Leu-Pro-Pro-Arg
  • Oligopeptides
  • Vascular Endothelial Growth Factor A
  • Neuropilin-1
  • Receptors, Vascular Endothelial Growth Factor
Topics
  • Animals
  • Diabetes Mellitus, Experimental (drug therapy, metabolism)
  • Diabetic Retinopathy (metabolism, prevention & control)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuropilin-1 (antagonists & inhibitors, metabolism)
  • Oligopeptides (pharmacology, therapeutic use)
  • Oxidative Stress (drug effects)
  • Receptors, Vascular Endothelial Growth Factor (metabolism)
  • Retinal Vessels (drug effects, metabolism)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: